.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Dow
Fuji
Medtronic
Federal Trade Commission
Novartis
Cipla
QuintilesIMS
Boehringer Ingelheim
Citi

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204082

« Back to Dashboard

NDA 204082 describes DESVENLAFAXINE SUCCINATE, which is a drug marketed by Actavis Labs Fl, Alembic Pharms Ltd, Lupin Ltd, Mylan Pharms Inc, Sandoz Inc, West-ward Pharms Int, and Zydus Pharms Usa Inc, and is included in eight NDAs. It is available from six suppliers. Additional details are available on the DESVENLAFAXINE SUCCINATE profile page.

The generic ingredient in DESVENLAFAXINE SUCCINATE is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.

Summary for 204082

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Formulation / Manufacturing:see details

Medical Subject Heading (MeSH) Categories for 204082

Suppliers and Packaging for NDA: 204082

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204082 ANDA West-Ward Pharmaceuticals Corp. 0054-0400 0054-0400-13 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0054-0400-13)
DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204082 ANDA West-Ward Pharmaceuticals Corp. 0054-0400 0054-0400-22 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0054-0400-22)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 50MG BASE
Approval Date:Feb 16, 2016TE:ABRLD:No
Regulatory Exclusivity Expiration:Aug 28, 2017
Regulatory Exclusivity Use:PATENT CHALLENGE

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 25MG BASE
Approval Date:Aug 28, 2017TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Fuji
Boehringer Ingelheim
Chinese Patent Office
Julphar
UBS
Johnson and Johnson
Farmers Insurance
Covington
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot